The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials

Ettore Beghi, Adriano Chiò, Philippe Couratier, Jesùs Esteban, Orla Hardiman, Giancarlo Logroscino, Andrea Millul, Douglas Mitchell, Pierre Marie Preux, Elisabetta Pupillo, Zorica Stevic, Robert Swingler, Bryan J. Traynor, Leonard H. Van Den Berg, Jan H. Veldink, Stefano Zoccolella

Research output: Contribution to journalArticlepeer-review

Abstract

Effective treatments for amyotrophic lateral sclerosis (ALS) have remained elusive. Only riluzole, a drug thought to affect glutamate metabolism, improves survival albeit to modest extent. Explanations for the negative results of therapeutic trials include a likely heterogeneity, both in disease susceptibility and pathogenic mechanisms, and faulty methodology of clinical trials. Further understanding of these factors will lead to improvements in patient stratification, and in the design of future clinical trials.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalAmyotrophic Lateral Sclerosis
Volume12
Issue number1
DOIs
Publication statusPublished - Jan 2011

Keywords

  • Amyotrophic lateral sclerosis
  • diagnosis
  • epidemiology
  • systematic review
  • treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint

Dive into the research topics of 'The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials'. Together they form a unique fingerprint.

Cite this